The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Co-distribution agreement with Elemental Machines

11 Mar 2021 07:00

RNS Number : 8628R
DeepMatter Group PLC
11 March 2021
 

11 March 2021

 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter signs co-distribution agreement with Elemental Machines

Providing expanded marketing footprint in the US

 

DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce it has signed a co-distribution agreement with Elemental Machines, the US based organisation helping biotechnology and pharmaceutical companies identify research problems through its sensor-based products.

 

This agreement will see Elemental Machines promote DeepMatter's integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware®, to its wide network of small and mid-size biotech North American customers through its sales team, presenting the Group with the opportunity to broaden its customer base and help establish sales opportunities across North America with organisations in the pharmaceutical and biotechnology sectors. DeepMatter will promote Elemental Machines' sensor-based products to its established European network who are interested in a wider sphere of real-time digital inputs for monitoring their laboratory environment, thereby expanding the number of laboratory devices which can integrate with the DigitalGlassware® platform.

 

Founded in 2015 by serial entrepreneur Sridhar Iyengar, Elemental Machines aims to enable reproducibility among the life sciences by using sensory equipment to gather and assess critical variables in the laboratory that can influence the result of an experiment. Their platform empowers LabOps Professionals to proactively run their labs. It currently works with over 200 customers, primarily in North America.

 

Mark Warne, CEO of DeepMatter, commented: "Elemental Machines is an organisation which shares our values of innovation and the pursuit of scientific discovery, and we're pleased to be advancing these with this collaboration. Importantly, this co-distribution agreement provides us with the capability to cast a wider net in North America, and we are very much looking forward to working with Elemental Machines as we capitalise upon this opportunity."

 

Sridhar Iyengar, CEO of Elemental Machines said: "Like Elemental Machines, DeepMatter is another organisation which recognises the enormous potential for the digitisation of chemistry. We believe that DigitalGlassware® is the most effective tool in the market for solving the reproducibility problem and the product offering will resonate well with our customer base.

 

"With both our customers set to benefit from the additional offerings we can now present, I look forward to seeing the difference we can make together in building labs fit for the future."

 

 

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Canaccord Genuity Limited (Nominated Advisor and Broker)

 

T: 020 7523 8000

Bobbie Hilliam / Angelos Vlatakis

 

 

Alma PR

T: 020 3405 0205

Caroline Forde / Harriet Jackson / Kieran Breheny / Faye Calow

deepmatter@almapr.co.uk

 

 

About DeepMatter Group plc 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. It has developed and is commercialising data rich platform technologies, including software and laboratory hardware, focused on applications to improve R&D productivity and discovery using Machine Learning / Artificial Intelligence. 

 

DeepMatter's technologies allow chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. They are designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster. 

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXDEFDLFEFA
Date   Source Headline
13th Apr 20167:00 amRNSPreliminary Results
21st Oct 20157:00 amRNSCompletion of Capital Reorganisation
7th Oct 20151:56 pmRNSResult of Court Hearing
29th Sep 20153:33 pmRNSHolding(s) in Company
28th Sep 201510:02 amRNSHolding(s) in Company
16th Sep 20157:00 amRNSChange of Name
15th Sep 20153:32 pmRNSHolding(s) in Company
15th Sep 201510:02 amRNSDirectors' Interest in Shares
15th Sep 201510:01 amRNSDirectorate Changes
15th Sep 201510:00 amRNSCompletion of Placing and Acquisition
11th Sep 201510:00 amRNSApplication for Admission
10th Sep 201511:16 amRNSResult of General Meeting
25th Aug 20155:10 pmRNSHalf Yearly Report
25th Aug 20155:05 pmRNSAcquisition and related matters
7th Jul 20157:00 amRNSChange of Name
30th Jun 201512:10 pmRNSResult of AGM
4th Jun 20158:35 amRNSReplacement: Final Results
4th Jun 20157:00 amRNSDirectorate Change
4th Jun 20157:00 amRNSFinal Results
8th Jan 20155:56 pmRNSHolding(s) in Company
9th Sep 20147:00 amRNSCompletion of investment in subsidiary
29th Aug 20147:00 amRNSHalf Yearly Report
14th Jul 201411:00 amRNSResult of AGM
30th Jun 20147:00 amRNSFirst commercial sale
17th Jun 20147:00 amRNSFinal Results
17th Mar 20147:00 amRNSGraphene Functionalisation Capabilities
3rd Feb 20147:00 amRNSProject Announcement
24th Jan 20147:00 amRNSOAS launches OntoTM Development Pack for customer
18th Nov 20135:43 pmRNSHolding(s) in Company
30th Oct 20137:00 amRNSDirectorate Change
18th Oct 20137:00 amRNSChange to substantial shareholdings
20th Sep 20137:00 amRNSDirectorate Change
28th Aug 20139:40 amRNSHalf Yearly Report
13th Jun 20135:30 pmRNSAGM Statement
1st May 20137:00 amRNSFinal Results
12th Apr 20131:10 pmRNSHolding(s) in Company
13th Mar 20138:42 amRNSHolding(s) in Company
12th Mar 20138:37 amRNSHolding(s) in Company
6th Mar 20134:03 pmRNSHolding(s) in Company
9th Jan 20137:00 amRNSTechnical Advisory Board Enhanced
7th Jan 20134:25 pmRNSHolding(s) in Company
20th Dec 20121:55 pmRNSHolding(s) in Company
5th Dec 20125:33 pmRNSHolding(s) in Company
12th Nov 20128:51 amRNSHolding(s) in Company
3rd Oct 20127:00 amRNSDirectors' Interest in Shares
26th Sep 20127:00 amRNSInterim Statement
24th Sep 20129:58 amRNSHolding(s) in Company
17th Sep 20129:26 amRNSHolding(s) in Company
1st Aug 20127:00 amRNSAppointment of CEO
15th Jun 201212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.